Lakshmanan I, et al. (2012) MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 31, 805-17 21785467

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T183-p - JNK1 (human) ▲
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene Orthologous residues JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MUC16 (human) decrease MUC16 shRNA increase

Y185-p - JNK1 (human) ▲
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene Orthologous residues JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MUC16 (human) decrease MUC16 shRNA increase

T183-p - JNK2 (human) ▲
Modsite: ACtNFMMtPyVVtRY SwissProt Entrez-Gene Orthologous residues JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MUC16 (human) decrease MUC16 shRNA increase

Y185-p - JNK2 (human) ▲
Modsite: tNFMMtPyVVtRYYR SwissProt Entrez-Gene Orthologous residues JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MUC16 (human) decrease MUC16 shRNA increase

Y705-p - STAT3 (human) ▲

Modsite: DPGsAAPyLktKFIC SwissProt Entrez-Gene Orthologous residues STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  MDA-MB-231 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MUC16 (human) increase MUC16 shRNA decrease